"BTK inhibitors are drugs that target and block Bruton's Tyrosine Kinase (BTK), an important player in the B-cell signaling pathway, critical for the growth, survival, and proliferation of B-cells."
"Unlike chemotherapies, BTK inhibitors are designed to target and kill only the malignant B-cells, resulting in much less toxicity compared to traditional treatments."
"Many clinical practice guidelines include BTK inhibitors in the treatment of a number of blood malignancies, such as chronic lymphocytic leukemia and mantle cell lymphoma."
BTK inhibitors are targeted therapies that block Bruton's Tyrosine Kinase, essential for B-cell signaling. They are effective in treating blood cancers like chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia. These drugs specifically target malignant B-cells, leading to decreased proliferation and increased cancer cell death, making them less toxic than traditional chemotherapies. Clinical guidelines recommend BTK inhibitors for first-line and relapsed treatments, highlighting their importance in managing hematologic malignancies.
Read at Alternative Medicine Magazine
Unable to calculate read time
Collection
[
|
...
]